So are we about to pop?
John Tobey argues in Forbes that “the biotech decline is not a bubble bursting. Rather, it’s one of those “typical” adjustment periods following a steady run-up.”
Maybe so. In The Burrill Report podcast, Dan Levine gets the candid opinions of Adam Feuerstein, senior columnist with TheStreet.com, about the wild ride in March, and asks if he thinks there’s any reason to be worried about a bubble.
The podcast can be listened to here.